Table 3.
Multivariate analysis of MYC expression and prognostic scoring systems for progression-free survival and overall survival in all patients with PCNS-DLBCL
| PFS | OS | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR | 95 % CI | P | ||
| Age | 0.989 | 0.949-1.032 | 0.614 | Age | 1.074 | 1.002–1.151 | 0.044 |
| MYC ≥ 40 | 1.745 | 0.848–3.589 | 0.130 | BCL2 ≥ 30 | -a | -a | 0.951 |
| N-B, 2-3 | 2.243 | 1.072–4.693 | 0.032 | N-B, 2-3 | 1.392 | 0.474–4.084 | 0.547 |
| MSKCC, 2–3 | 2.635 | 0.502–13.827 | 0.252 | MSKCC, 2–3 | 0.370 | 0.048–2.841 | 0.339 |
Abbreviations: PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, N-B Nottingham-Barcelona, MSKCC Memorial Sloan Kettering Cancer Center
(avalues are not shown.)